6 terminated. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Terminated 6 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia Outpatient Care Model, CPX-351 - Leukemia, Myeloid, Acute | Phase 4 | Terminated | Medical College of Wisconsin | 3 | 2019-08-28 | 2022-07-19 |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Bosutinib - Previously Treated PH + CML | Phase 4 | Terminated | Pfizer | 163 | 2014-11-07 | 2021-12-30 |
| A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients 600mg/day of Imatinib, 400mg/day of Imatinib - Chronic Myeloid Leukemia | Phase 4 | Terminated | Dong-A ST Co., Ltd. | 55 | 2014-10-13 | 2018-06-15 |
| Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Nilotinib 300 mg. - Myeloid Leukemia, Chronic | Phase 4 | Terminated | King Abdullah International Medical Research Center | 98 | 2013-03-01 | 2017-03-07 |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations nilotinib - CML, Philadelphia Chromosome Positive (Ph+) | Phase 4 | Terminated | Novartis Pharmaceuticals | 3 | 2010-10-21 | 2021-05-20 |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib bone marrow aspiration - Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors | Phase 4 | Terminated | University Health Network, Toronto | 68 | 2005-02-01 | 2009-02-13 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia (2) · Bronchiolitis Obliterans Syndrome (1) · Chromosome Aberrations (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (5) · Chronic Disease (5) · Disease Attributes (5) · Myeloproliferative Disorders (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Leukemia (4) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1)
nilotinib (2) · CPX-351 (1) · Cytarabine (1) · Imatinib Mesylate (1) · bosutinib (1)
Dong-A ST Co., Ltd. (1) · King Abdullah International Medical Research Center (1) · Medical College of Wisconsin (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · University Health Network, Toronto (1)
United States (3) · Austria (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Norway (1) · Saudi Arabia (1) · South Korea (1) · Spain (1) · Sweden (1)
Chul-won Choi, M.D. (1) · Chul-won Jung, M.D. (1) · Dr. Ahmad S. Alaskar, MD,FACP,FRCP (1) · Duk-yeon Cho, M.D. (1) · Jeff Lipton, MD (1) · Jin-hee Park, M.D. (1) · Joo-sup Joeng, M.D. (1) · Joon-sung Park, M.D. (1) · Jung-ok Lee, M.D. (1) · Kyu-Hyoung Lee, M.D. (1) · Kyung-ha Kim, M.D. (1) · Laura Michaelis, MD (1) · Martin Blackstein, MD (1)
PMID 32572189, PMID 35235189, PMID 38007586, PMID 38484432, PMID 39164407